symmetric dimethylarginine has been researched along with Metabolic Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Atzler, D; Böger, RH; Duncan, MS; Hannemann, J; Maas, R; Moser, C; Schwedhelm, E; Vasan, RS; Xanthakis, V; Yola, IM | 1 |
| Collin, B; Cottin, Y; Duvillard, L; Goirand, F; Guilland, JC; Korandji, C; Lauzier, B; Moreau, D; Rochette, L; Sicard, P; Vergely, C; Zeller, M | 1 |
| Böger, RH | 1 |
1 review(s) available for symmetric dimethylarginine and Metabolic Syndrome
| Article | Year |
|---|---|
Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Topics: Arginine; Arteriosclerosis; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Endothelium, Vascular; Female; Humans; Hyperthyroidism; Insulin Resistance; Liver Failure; Male; Metabolic Syndrome; Nitric Oxide; Nitric Oxide Synthase; Pre-Eclampsia; Pregnancy; Risk Factors; Stereoisomerism | 2006 |
2 other study(ies) available for symmetric dimethylarginine and Metabolic Syndrome
| Article | Year |
|---|---|
Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study.
Topics: Arginine; Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Prevalence; Prospective Studies; Tandem Mass Spectrometry | 2021 |
Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome.
Topics: Animals; Aorta; Arginine; Blood Glucose; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fructose; Heart Rate; Hypertension; Male; Metabolic Syndrome; NADPH Oxidases; Nitric Oxide Synthase Type II; Oxidative Stress; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine; Vasodilation; Vasodilator Agents | 2011 |